Literature DB >> 27298401

Valproate in Adjuvant Glioblastoma Treatment.

Michael F Fay1, Richard Head2, Peter Sminia3, Nicholas Dowson4, Leah Cosgrove5, Stephen E Rose6, Jenny H Martin7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27298401     DOI： 10.1200/JCO.2016.67.2162

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.

Authors:  Nataly Tarasenko; Abraham Nudelman; Gabriela Rozic; Suzanne M Cutts; Ada Rephaeli
Journal:  Invest New Drugs       Date:  2017-03-17       Impact factor: 3.850

Review 2.  Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.

Authors:  Peter Mathen; Lindsay Rowe; Megan Mackey; DeeDee Smart; Philip Tofilon; Kevin Camphausen
Journal:  Neurooncol Pract       Date:  2019-11-30

Review 3.  Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Authors:  R J Head; M F Fay; L Cosgrove; K Y C Fung; D Rundle-Thiele; J H Martin
Journal:  Cancer Biol Ther       Date:  2017-11-20       Impact factor: 4.742

4.  Effect of valproic acid on survival in glioblastoma: A prospective single-arm study.

Authors:  Deepthi Valiyaveettil; Monica Malik; Deepa M Joseph; Syed Fayaz Ahmed; Syed Akram Kothwal; M Vijayasaradhi
Journal:  South Asian J Cancer       Date:  2018 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.